‘Add-on’ approaches to ruxolitinib being studied in clinical trials.
| Agent (class) | Drug class | Phase (NCT number) | Reference |
|---|---|---|---|
| CPI-0610 | BET inhibitor | 2 (NCT02158858) | Mascarenhas |
| Navitoclax | BCL-2/BCL-xL antagonist | 2 (NCT03222609) | Harrison |
| Umbralisib | PI3Kδ inhibitor | 1 (NCT02493530) | Moyo |
| Parsaclisib | PI3Kδ inhibitor | 2 (NCT02718300) | Daver |
| Idelalisib | PI3Kδ inhibitor | 1 (NCT02436135) | - |
Blood Res 2021;56:S26~S33 https://doi.org/10.5045/br.2021.2020325
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd